Literature DB >> 31474549

Multicentric validation of radiomics findings: challenges and opportunities.

Mathieu Hatt1, François Lucia2, Ulrike Schick2, Dimitris Visvikis3.   

Abstract

Entities:  

Year:  2019        PMID: 31474549      PMCID: PMC6796519          DOI: 10.1016/j.ebiom.2019.08.054

Source DB:  PubMed          Journal:  EBioMedicine        ISSN: 2352-3964            Impact factor:   8.143


× No keyword cloud information.
Predicting patients' outcome after treatment is challenging. Usual clinical variables and standard exploitation of imaging fails to deliver actionable predictive models with sufficient accuracy in a number of cancer types and associated treatments, including cervical cancer, one of the most frequent malignant tumour in women with over 500,000 cases annually worldwide, associated with 270,000 deaths [1]. For women diagnosed with locally advanced cervical cancer (LACC), treatment in Western countries is usually pelvic external beam radiotherapy (EBRT) in association with cisplatin-based chemotherapy (CRT), followed by brachytherapy (BT). Alternatively, preoperative neoadjuvant chemotherapy (NACT) is increasingly being considered in Asian countries in order to reduce tumour volumes and allow for a surgical removal. Within this context, there is a crucial need to identify biomarkers predictive of outcome, in order to personalize treatment. Radiomics has emerged as a potential solution to provide such biomarkers from available routine pre-treatment images, by considering that the content of images can be extracted through machine (deep) learning, beyond the capabilities of the human eye, even the expertly-trained one [2,3]. The resulting features can be mined, similarly to other -omics domains, in order to identify the relevant ones. One advantage of radiomics is that it exploits diagnostic images that are available already, so it does not require additional exams (imaging or biological). Despite a number of encouraging results, radiomics faces challenges that have until now prevented its widespread use in clinical practice. These include false-positives [4], the lack of standards and resulting limited reproducibility [5], the lack of fully automated detection and delineation, and the lack of multi-centric validation [6]. This last point is addressed within the context of LACC by the study by Sun, et al. recently published in EBioMedicine [7]. They investigated the prediction of response to NACT in LACC using radiomic features extracted from pre-treatment magnetic resonance imaging (MRI) T1 and T2 sequences. They included 275 patients from 8 cohorts (5 were used as a training set, 3 as the testing set). IBSI (image biomarkers standardization initiative)-compliant radiomic features were extracted from the two MRIs, as well as from both the intratumoural and the peritumoural regions manually delineated by radiologists. In the training set, a support vector machine with recursive feature elimination was exploited to identify the most relevant features. Then a random forest was used to build models, which were then evaluated in the testing set. Importantly, the robustness of the findings was evaluated by training/testing the models on different training and testing sets. The models based on a single sequence and single tumour region reached AUCs ≥ 0.94, with 100% specificity but limited sensitivity (76% at best). Those based on combinations of sequences reached AUCs ≥ 0.98, with 100% specificity and sensitivity up to 84% for the best model. Moreover, these results were robust to different splitting of the data into training and testing sets. In a subset of 232 patients for which the clinical variables (age, FIGO stage, gross type) were available, the radiomic models significantly outperformed the model based on clinical features (AUC of 0.6). This is in line with the results of Lucia, et al. with the radiomic model reaching an accuracy of 0.90–0.97 versus 0.56–0.60 for the clinical model [8]. One challenging aspect of multicentric radiomic studies is the sensitivity of radiomic features with respect to the variability of scanner models, acquisition protocols and reconstruction algorithms and parameters. Recently, a radiomic model exploiting FDG positron emission tomography (PET) and MRI apparent coefficient diffusion (ADC) map to predict outcome in LACC was validated in a multicentric context (3 different centers), thanks to the use of the ComBat harmonization technique [8]. In that respect, the study of Sun, et al. showed that z-score normalization [9] of each slice of the MR images intensities as well as of the features of each patient could allow good performance, despite different 3.0-T and 1.5-T MRI scanner models from several different vendors across the 8 centres. One important limitation of the study by Sun, et al. is that regions of interest were manually delineated. Although reproducibility was evaluated through blind analysis by two radiologists, a fully automated delineation will need to be developed so the proposed radiomic model can be exploited clinically. Artificial intelligence has already shown the potential of highly accurate image segmentation within the multimodality imaging context [10]. Another limitation is that clinical data were not available for all patients, compromising the comparison between the radiomic models and standard clinical variables carried out only on a subsample of the overall study population. Finally, the models might not be directly applicable to cohorts in the Western countries for which treatment management differ. Nonetheless, the work by Sun, et al. contributes to the growing number of studies that show validating radiomic models in a multicentric context is feasible. Such results may help the radiomics approach to translate faster into the clinical routine practice.

Author disclosure

The authors declare no conflicts of interest.
  7 in total

1.  External validation of a combined PET and MRI radiomics model for prediction of recurrence in cervical cancer patients treated with chemoradiotherapy.

Authors:  François Lucia; Dimitris Visvikis; Martin Vallières; Marie-Charlotte Desseroit; Omar Miranda; Philippe Robin; Pietro Andrea Bonaffini; Joanne Alfieri; Ingrid Masson; Augustin Mervoyer; Caroline Reinhold; Olivier Pradier; Mathieu Hatt; Ulrike Schick
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-12-07       Impact factor: 9.236

2.  Artificial intelligence, machine (deep) learning and radio(geno)mics: definitions and nuclear medicine imaging applications.

Authors:  Dimitris Visvikis; Catherine Cheze Le Rest; Vincent Jaouen; Mathieu Hatt
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-07-06       Impact factor: 9.236

3.  Radiomics in PET/CT: More Than Meets the Eye?

Authors:  Mathieu Hatt; Florent Tixier; Dimitris Visvikis; Catherine Cheze Le Rest
Journal:  J Nucl Med       Date:  2016-11-03       Impact factor: 10.057

4.  Responsible Radiomics Research for Faster Clinical Translation.

Authors:  Martin Vallières; Alex Zwanenburg; Bodgan Badic; Catherine Cheze Le Rest; Dimitris Visvikis; Mathieu Hatt
Journal:  J Nucl Med       Date:  2017-11-24       Impact factor: 10.057

5.  Vulnerabilities of radiomic signature development: The need for safeguards.

Authors:  Mattea L Welch; Chris McIntosh; Benjamin Haibe-Kains; Michael F Milosevic; Leonard Wee; Andre Dekker; Shao Hui Huang; Thomas G Purdie; Brian O'Sullivan; Hugo J W L Aerts; David A Jaffray
Journal:  Radiother Oncol       Date:  2018-11-08       Impact factor: 6.280

6.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

7.  Radiomic analysis for pretreatment prediction of response to neoadjuvant chemotherapy in locally advanced cervical cancer: A multicentre study.

Authors:  Caixia Sun; Xin Tian; Zhenyu Liu; Weili Li; Pengfei Li; Jiaming Chen; Weifeng Zhang; Ziyu Fang; Peiyan Du; Hui Duan; Ping Liu; Lihui Wang; Chunlin Chen; Jie Tian
Journal:  EBioMedicine       Date:  2019-08-06       Impact factor: 8.143

  7 in total
  5 in total

1.  Effects of Tracer Uptake Time in Non-Small Cell Lung Cancer 18F-FDG PET Radiomics.

Authors:  Guilherme D Kolinger; David Vállez García; Gerbrand Maria Kramer; Virginie Frings; Gerben J C Zwezerijnen; Egbert F Smit; Adrianus Johannes de Langen; Irène Buvat; Ronald Boellaard
Journal:  J Nucl Med       Date:  2021-12-21       Impact factor: 11.082

2.  Performance comparison of modified ComBat for harmonization of radiomic features for multicenter studies.

Authors:  D Visvikis; M Hatt; R Da-Ano; I Masson; F Lucia; M Doré; P Robin; J Alfieri; C Rousseau; A Mervoyer; C Reinhold; J Castelli; R De Crevoisier; J F Rameé; O Pradier; U Schick
Journal:  Sci Rep       Date:  2020-06-24       Impact factor: 4.379

3.  Identifying Robust Radiomics Features for Lung Cancer by Using In-Vivo and Phantom Lung Lesions.

Authors:  Lin Lu; Shawn H Sun; Aaron Afran; Hao Yang; Zheng Feng Lu; James So; Lawrence H Schwartz; Binsheng Zhao
Journal:  Tomography       Date:  2021-02-09

4.  Accurate Tumor Delineation vs. Rough Volume of Interest Analysis for 18F-FDG PET/CT Radiomics-Based Prognostic Modeling inNon-Small Cell Lung Cancer.

Authors:  Shima Sepehri; Olena Tankyevych; Andrei Iantsen; Dimitris Visvikis; Mathieu Hatt; Catherine Cheze Le Rest
Journal:  Front Oncol       Date:  2021-10-18       Impact factor: 6.244

5.  Pretreatment Prediction of Relapse Risk in Patients with Osteosarcoma Using Radiomics Nomogram Based on CT: A Retrospective Multicenter Study.

Authors:  Jin Liu; Tao Lian; Haimei Chen; Xiaohong Wang; Xianyue Quan; Yu Deng; Juan Yao; Ming Lu; Qiang Ye; Qianjin Feng; Yinghua Zhao
Journal:  Biomed Res Int       Date:  2021-02-04       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.